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Hypertension in chronic renal disease and renovascular disease is often resistant to therapy. Understanding the pathogenic
mechanisms responsible for hypertension in these conditions may lead to improved and more targeted therapeutic interventions.
Several factors have been implicated in the pathogenesis of hypertension associated with renal disease and/or renal failure.
Although the role of sodium retention, total body volume expansion, and hyperactivity of the renin-angiotensin-aldosterone
system (RAAS) are well recognized, increasing evidence suggests that aﬀerent impulses from the injured kidney may increase
sympathetic nervous system activity in areas of the brain involved in noradrenergic regulation of blood pressure and contribute
to the development and maintenance of hypertension associated with kidney disease. Recognition of this important pathogenic
factor suggests that antiadrenergic drugs should be an essential component to the management of hypertension in patients with
kidney disease, particularly those who are resistant to other modalities of therapy.
1. HypertensionResistant to Therapy in
PatientswithRenovascularDiseaseand
withChronicKidney Disease
Although the majority of patients with resistant hyper-
tension have essential hypertension, secondary forms of
hypertension are more commonly seen in patients with
resistant hypertension. Among the most common causes of
secondary hypertension are renovascular hypertension and
hypertension secondary to chronic kidney disease (CKD).
Renovascular hypertension accounts for 2-3% of patients
with hypertension and is often diﬃcult to control. Reno-
vascular disease is present in 30% of patients with grade 3
or 4 hypertensive retinopathy [1]. In one study, 16.7% of
clinically selected patients had renovascular hypertension,
as documented by blood pressure response to correction of
renal artery stenosis or removal of the involved kidney [2].
Hypertension is very prevalent among patients with
CKD and it contributes to the high prevalence of cardio-
vascular disease and progression of kidney disease in these
patients (Table 1)[ 3–6]. Hypertension associated with renal
parenchymal disease constitutes approximately 5% of all
forms of hypertension, and it becomes more frequent as
patient progress toward end-stage renal disease (ESRD).
Nearly 85% of ESRD patients have hypertension. Hyper-
tension is the single most important predictor of coronary
artery disease in ESRD patients, even more so than other
known cardiovascular risk factors [7]. Often, treatment of
hypertension in ESRD patients is diﬃcult and inadequate.
Understanding the mechanisms of hypertension may help
improve therapy in such patient populations.
2. Evidence for Activation of the Sympathetic
NervousSystem(SNS)inRenovascular
Hypertensionand Kidney Disease
The renin-angiotensin-aldosterone system (RAAS) plays a
key role in blood pressure (BP) elevation in the early phase
of renovascular hypertension. Later on, other mechanisms
such as sodium retention and activation of the sympathetic
nervous system (SNS) may contribute to hypertension
[8, 9]. In one study, sixty-ﬁve patients with hypertension
and renovascular disease demonstrated by angiography
underwent measurements of plasma renin activity and2 International Journal of Hypertension
Table 1: Factors implicated in the pathogenesis of hypertension in
end-stage renal disease.
Sodium and volume excess
The renin-angiotensin-aldosterone system
The sympathetic nervous system
Endothelium-derived vasodepressor substances
Endothelium-derived vasoconstrictor substances
Erythropoietin use
Divalent ions and parathyroid hormone
Atrial natriuretic peptide
Structural changes in the arteries
Pre-existent essential hypertension
Miscellaneous
Anemia/ Hypoxia
A-V ﬁstula
Vasopressin
Serotonin
Thyroid function
Calcitonin gene-related peptide
angiotensin II in conjunction with estimation of SNS activity
by means of radiotracer dilution and intraneural recordings
of muscle sympathetic nerve activity (MSNA) [8]. Total
body norepinephrine (NE) spillover, an index of overall SNS
activity, was increased by 100% and MSNA by 60% in the
hypertensive patients compared with healthy subjects, which
supports the role of SNS activity in the maintenance of
hypertension in these patients [8].
The pathogenesis of hypertension in patients with CKD
is multifactorial and may vary depending on the underlying
disease (Table 1). Activation of the RAAS, sodium retention,
and volume expansion have long been recognized as the
mostimportantfactors[10,11].However,clinicalexperience
indicates that volume depletion and inhibition of the RAAS
donotnecessarilyresultinnormalizationofBP.Thissuggests
that other factors may play a role. Among those, activation of
the SNS appears to have a prominent role.
PlasmaNElevelsarefrequentlyincreasedinhemodialysis
patients [12, 13] and in patients with early CKD and
hypertension compared with healthy subjects and with nor-
motensive CKD patients [14]. Direct recording of neuronal
activity from postganglionic MSNA in the peroneal nerves
of patients on chronic dialysis treatment has shown a
greater rate of SNS discharge than in control subjects [15].
Moreover, MSNA in hypertensive hemodialysis patients with
native kidneys were 2.5 times more frequent than those
in hemodialysis patients after bilateral nephrectomy or in
healthy subjects. Our studies on 5/6 nephrectomized rats
have provided the most convincing evidence yet for a role
of the sympathetic nervous system in the pathogenesis of
hypertension associated with CKD [16]. The turnover rate
of NE, which is a marker of SNS activity, was greater in
two areas of the brain involved in the noradrenergenic
control of BP (posterior hypothalamic (PH) nuclei and the
locus coeruleus) of CKD rats compared to that of control
rats. Moreover, microinjection of a neurotoxin, 6-hydroxy-
dopamine, in the PH signiﬁcantly reduced BP in CKD rats
[17]. The secretion of NE from the PH was also greater in
CKD rats than in control animals [16]. We postulated that
the activation of these nuclei in the central nervous system
results from impulses generated in the aﬀected kidney which
are transmitted to the central nervous system.
The kidney is richly innervated with baroreceptors and
chemoreceptors[18–20].Renalaﬀerentnervesareconnected
directly or indirectly to a number of areas in the central
nervous system that contribute to BP regulation [21]. Stim-
ulation of renal receptors by adenosine, urea, or electrical
impulses evoke reﬂex increases in SNS activity and BP
[22, 23]. Renal aﬀerent impulses play an important role in
the genesis of hypertension in several other experimental
models, including the one-kidney one-clip and two-kidney
one-clip Goldblatt hypertension in rats, the one-kidney one-
wrap Grollman hypertension in the rat, or in the spon-
taneously hypertensive rat (SHR) [24–27]. Furthermore,
bilateral dorsal rhizotomy at the level T-10 to L-3 resulted in
almost complete normalization of BP in 5/6 nephrectomized
rats [28]. This suggests that increased renal sensory inputs
from the injured kidney to the central nervous system may
contribute to the development of hypertension in CKD rats.
Kidney damage can raise BP even in the absence of renal
insuﬃciency.Theinjectionofphenolinthelowerpoleofone
kidney leads to an immediate elevation of BP and activation
of the central SNS activity, which can be prevented by renal
denervation [16, 29]. There is also convincing evidence
that the SNS plays an important role in the pathogenesis
of hypertension observed in patients with CKD caused by
polycystic kidney disease [30].
However, not all types of injury to the kidney lead
to an increase in blood pressure. For example, burning,
administration of alkali, acids, or methanol caused no
eﬀects [29]. This is of relevance, since clinical experience
indicates that not all renal injuries in humans are associated
with hypertension. For example, in the absence of renal
insuﬃciency, IgA nephropathy is more likely to be associated
with hypertension than membranous glomerulonephritis
or minimal change disease (Table 2)[ 31]. These ﬁndings
support the notion that increased aﬀerent nervous inputs
from kidneys with renal diseases may send signals to
integrative sympathetic nuclei in the central nervous system
and contribute to the pathogenesis of hypertension. The
normalization of BP that follows bilateral nephrectomy may
be largely due to elimination of these aﬀerent impulses.
Identiﬁcation of the factor(s) responsible for the
intrarenal activation of these aﬀerent pathways, or for the
stimulation of sympathetic output from the brain, may
lead to a new understanding of the pathophysiology of
sympathetic overactivity and hypertension in renal disease
and,hopefully,tonoveltherapiesbasedonspeciﬁcinhibitors
of these activating factors.International Journal of Hypertension 3
Table 2: Prevalence of hypertension secondary to underlying renal
parenchymal disease.
Acute renal failure 40%
caused by glomerular-vascular disease 73%–90%
caused by tubulointerstitial disease 10%–15%
Acute poststreptococcal
glomerulonephritis
60%–80%
Primary focal and segmental
glomerulosclerosis
45% nephrotic
65% non-nephrotic
Minimal-change disease Rare
Membranous glomerulonephritis 10%
Membranoproliferative
glomerulonephritis
30%
Mesangial proliferative
glomerulonephritis
33%
IgA nephropathy 25%–36%
Autosomal dominant polycystic kidney
disease
50%–80%
Chronic pyelonephritis 33%
Wilms tumor 50%
Adenocarcinoma of the kidney 38%
Reﬂux nephropathy 20%
Renal tuberculosis 4%
End-stage renal disease 80%–90%
caused by chronic glomerulonephritis 78%
caused by hypertensive nephrosclerosis 100%
caused by diabetic nephropathy 80%
3. Mechanisms of SNS Activation in
KidneyDisease
3.1. Angiotensin II. T h ea c t i v a t i o no ft h eS N Si nC K D
may be related to the eﬀects of circulating angiotensin II
(Ang II) released from the kidneys. We have previously
shown that intracerebroventricular (ICV) infusion of Ang II
raises BP, renal sympathetic nervous system activity (RSNA),
and NE secretion from the PH compared to control rats.
Pretreatment with losartan, an AT1 receptor blocker, given
as an ICV infusion 20min prior to the infusion of Ang II
completely abolished the eﬀects of Ang II on BP, RSNA, and
NE secretion from the PH [32].
Antagonists of the renin-angiotensin system, such
as angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II AT1 receptor antagonists, inhibit the produc-
tion of Ang II or its ability to bind to its receptor, resulting in
partial inhibition of the sympathetic nervous system in 5/6
nephrectomized rats [33], in the phenol-renal injury model
[34], as well as in humans with CKD [14, 30].
3.2. Oxidative Stress. Reactive oxygen species (ROS) are
involved in the regulation of SNS activity [35]. Increased
oxidative stress in key brain nuclei mediates the activation
of the SNS in the phenol-renal injury model of hypertension
[36] and in stroke-prone spontaneously hypertensive rats
[37]. Increased oxidative stress within the rostral ventral
lateral medulla (RVLM) and paraventricular nucleus (PVN)
was associated with hypertension and sympathetic over-
activity in the 2K 1C Goldblatt model of renovascular
hypertension [38], and superoxide signaling in the RVLM
was found to play a major role in sustained hypertension and
sympathetic nervous system activation in this model.
ROSarealsoinvolvedintheintracellularsignalingmech-
anisms of Ang II in the brain. [39, 40], in central SNS acti-
vation and BP elevation in experimental models of obesity-
induced hypertension [41], renovascular hypertension [38],
and salt-sensitive hypertension [42]. Moreover, chronic
antioxidant therapy improved oxidative stress and BP in a
rat model of renovascular hypertension [38]. Despite these
experimental data, antioxidants currently have no deﬁnitive
role in the management of hypertension in CKD patients.
3.3. Hypoxia. Substantial evidence suggests that kidney
ischemia may be responsible for sympathetic nervous system
activation in renal hypertension. This is supported by studies
in conscious rats with acute renal artery stenosis [21].
Restoration of renal perfusion in humans with renovascular
hypertension reduces MSNA to control levels and leads to
normalization of BP [43]. Regional hypoxia has also been
demonstrated in polycystic kidney disease by immunostain-
ing [44].
3.4. Nitric Oxide. Recent studies have provided convincing
evidence that nitric oxide synthase (NOS) is present in
speciﬁc area of the brain involved in the neurogenic control
of blood pressure [45, 46]. Studies on experimental animals
have also provided evidence that the neuronal isoform
of NOS is an important component of the transduction
pathways that tonically inhibit sympathetic outﬂow from the
brain stem [47–50]. In normal rats, the basal activity of the
central sympathetic nervous system is regulated by local NO
production. Evidence from our laboratory also indicates that
local production of NO may modulate sympathetic activity
in brain nuclei involved in the neurogenic regulation of BP
[51]. Reduced availability of NO in these brain nuclei, may
result in increased SNS activity and hypertension.
3.5. Cytokines. Complex relationships exist between SNS,
nitric oxide, and cytokines [52–55]. One possible mediator
for the increase in NO expression is interleukin 1β (IL-
1β). Our study has demonstrated for the ﬁrst time that
administration of IL-1β in the lateral ventricle of control
and CKD rats lowers BP and NE secretion from the PH [56].
Moreover, we have shown that the modulatory action of
IL-1β on SNS activity is mediated by increased expression of
neuronal NOS mRNA in the brain. Several lines of evidence
strongly support this conclusion. First, the administration of
IL-1β in the lateral ventricle of control and CKD rats caused
a dose-dependent decrease in BP and NE secretion from the
PH and an increase in neuronal NOS mRNA abundance in
the brain nuclei. Second, infusion of a speciﬁc anti-rat IL-1β
antibody in the lateral ventricle led to an elevation in BP
and secretion of NE from the PH of control rats, and to a4 International Journal of Hypertension
further rise in BP and NE secretion from the PH of CKD
rats. Third, the administration of an anti-rat IL-1β antibody
decreases NOS mRNA expression in the several brain nuclei
(PH, locus coeruleus, and paraventricular nuclei) of both
control and CKD rats. Finally, in CKD rats we observed an
increase in the abundance of IL-1β mRNA in all brain nuclei
tested. In all, these ﬁndings suggest that IL-1β modulates
the activity of the SNS via activation of neuronal NOS and
partially mitigates the rise in BP and SNS activity in CKD as
well as in control rats.
3.6. Treatment of Resistant Hypertension with Antiadrenergic
Agents. Given the evidence for the role of the sympathetic
nervous system in hypertension, antiadrenergic agents may
be considered in the treatment of hypertension, especially in
the setting of diﬃcult to control BP. The numerous antihy-
pertensive agents that have become available over the last few
decades have overshadowed the potential of centrally acting
agents such as clonidine and guanfacine in conventional
antihypertensive therapy. However, experimental evidence
has demonstrated the ability for these agents to decrease
peripheral SNS activity and BP. For example, in salt-sensitive
SHR, intrahypothalamic infusion of clonidine abolished
the hypertensive eﬀect of dietary salt supplementation and
decreased the salt-related increase in plasma NE seen in
control rats supplemented with dietary salt [57]. In operative
candidates, clonidine administration has been shown to
decrease plasma NE levels typically associated with the stress
of surgery in comparison to placebo [58]. We were the ﬁrst
to demonstrate that clonidine administration reduced SNS
activity and caused natriuresis in salt-sensitive patients with
essential hyperitension [59] and in patients with chronic
kidney disease [60, 61]. Further studies are needed in the
setting of resistant hypertension to determine the eﬃcacy of
antiadrenergic agents.
3.7. Catheter-Based Renal Denervation for the Treatment of
ResistantHypertension. Newadvancesintechnologyrecently
have brought about the translation of basic science ani-
mal models of therapy for resistant hypertension into the
forefront of current therapy for resistant hypertension. A
recent case report by Schlaich et al. describes a 59-year-
old patient on seven antihypertensive medications who
underwent renal sympathetic ablation of the aﬀerent renal
nerves, which resulted in a BP reduction to 127/81mgHg
from a baseline blood pressure of 161/107mmHg over a
twelve-month period [62]. A concomitant reduction of total
body norepinephrine spillover and plasma renin was noted.
A multicenter study involving 40 patients with resistant
hypertension on an average of four or more antihypertensive
medications who underwent ablation of the renal sympa-
thetic aﬀerent and eﬀerent nerves was recently published
[63]. An average BP reduction of 27mmHg systolic and
17mmHg diastolic was achieved, although the authors do
clarify that BP medications were adjusted and in some
patients, uptitrated after renal nerve ablation. Data on
noradrenaline spillover in this study correlated closely with
the reduction in BP, and the authors suggest that renal
sympathetic nerve ablation is a safe and eﬀective approach to
the treatment of resistant hypertension. Long-term followup
on patients undergoing renal sympathetic nerve denervation
willbeneededtodeterminethedurationofbeneﬁtandlong-
term safety of such an approach.
4. Conclusions andFutureDirections
SNS activation plays a major role in the pathogenesis of
resistant hypertension, particularly when it is due to renal
parenchymal or renovascular disease. Mechanisms responsi-
ble for increased SNS activity include intrarenal stimulation
of renal aﬀerent nerves, direct central eﬀects of angiotensin
II, oxidative stress, cytokines, and NO inhibition.
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